What is Confluence Pharmaceuticals?
Confluence Pharmaceuticals is a biotechnology firm dedicated to creating innovative treatments for neurological development disorders. The company's primary research efforts are concentrated on a novel drug discovery aimed at ameliorating social and communication impairments associated with Autism Spectrum Disorders and Fragile X Syndrome. This focus positions Confluence Pharmaceuticals within a critical and growing segment of the pharmaceutical market, addressing unmet medical needs with potentially life-changing therapies.
How much funding has Confluence Pharmaceuticals raised?
Confluence Pharmaceuticals has raised a total of $200K across 1 funding round:
Other Financing Round
$200K
Other Financing Round (2022): $200K with participation from UI Ventures
Key Investors in Confluence Pharmaceuticals
UI Ventures
UI Ventures is an investor participating in the funding round. Further details on their investment focus are not available.
What's next for Confluence Pharmaceuticals?
The substantial capital infusion, particularly the recent strategic investment, signals Confluence Pharmaceuticals' readiness to accelerate its drug development pipeline and potentially scale its operations. This late-stage funding context suggests the company is moving towards clinical trials and regulatory submissions, aiming to bring its therapeutic solutions to market. Future strategic moves will likely involve further research and development, expanding its therapeutic portfolio, and forging partnerships to enhance market penetration and patient access.
See full Confluence Pharmaceuticals company page
